Clinical-stage specialty pharmaceutical company, Savara, Inc. today announced the initiation of the AVAIL study, a Phase III, randomized, double-blind, placebo-controlled study of AeroVanc (vancomycin...

Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic being developed to address the growing number...